The company's $249.8 million in revenues missed the consensus Wall Street estimate, but its loss of $.05 per share beat analysts' average expectation.
The company attributed the growth to increasing global demand for breast cancer testing, and growing demand and reimbursement for its prostate test.
Almac is developing the assay to enroll patients for clinical trials used to develop repotrectinib, an investigational tyrosine kinase inhibitor.
The decision, issued by Medicare Administrative Contractor Palmetto GBA, is effective Dec. 10 and provides coverage of the test for about 25,000 Medicare patients.
The company aims to commercialize ProstaGene's PCaTest, which uses a 16-gene panel to determine the overall outcome of a patient's prostate cancer.
Though the firm's total revenues were down year over year, its product and service revenue soared on sales of its ConfirmMDx Prostate cancer assay.
DiaCarta scientists will partner with the University of Florida Health Cancer Center to analyze blood samples from up to 500 cancer patients undergoing radiotherapy.
The 72-SNP score is for men of European ancestry who don't have mutations in high penetrance risk genes or mutations in genes associated with aggressive disease.
Noridian GBA has issued the LCD for use of the Decipher Prostate Biopsy genomic classifier in patients with very low and low-risk prostate cancer.
The firm is preparing to launch a clinical trial for the AdxBladder test in the US early in 2019 and use the results to apply for 510(k) clearance with the FDA.